ALT Altimmune Inc.

-0.02  -1%
Previous Close 2.47
Open 2.46
Price To Book 0.56
Market Cap 32,912,640
Shares 13,450,750
Volume 18,634
Short Ratio
Av. Daily Volume 326,605

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial planned for 2020.
Hepatitis B
Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
Flu vaccine
Phase 1 data showed limited response.

Latest News

  1. Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
  2. Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business
  3. Altimmune to acquire California company for up to $93M
  4. Germantown stem cell therapy company proposes $7M offering amid delisting threat
  5. Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio
  6. Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma
  7. Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
  8. Altimmune Appoints Will Brown as Chief Financial Officer
  9. Altimmune Announces Successful Pre-IND Meeting with FDA
  10. Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
  11. Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update
  12. Altimmune to Announce First Quarter 2019 Financial Results on May 15
  13. Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
  14. Altimmune, Inc. to Host Earnings Call
  15. Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
  16. Altimmune to Announce Year End 2018 Financial Results on April 2
  17. Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
  18. Altimmune Announces Positive Results from NasoVAX Extension Study
  19. Altimmune to Participate at 31st Annual ROTH Conference